Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) Drug Overview 2018: A First-in-Class Oral Selective Non-Prostanoid Prostaglandin I2 (PGI2) Receptor Agonist

DUBLIN, June 26, 2019 /PRNewswire/ -- The "Uptravi" report has been added to ResearchAndMarkets.com's offering.

Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is a first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist. The drug and its active metabolite, ACT-333679, have a similar mode of action to the prostacyclin analogs, but with greater selectivity for the PGI2 receptor.

Analyst Outlook

Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is positioned to become the second highest-selling drug behind Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku) in the forecast period, with strong peak sales of $1.5bn across the forecast markets. Notably, Uptravi represents the first prostacyclin to launch for pulmonary hypertension (PH) supported by clinical data demonstrating a slowing of disease progression and reduced risk of hospitalization.

Furthermore, it is dosed orally, eliminating the need for the burdensome injections or regular inhalation with other prostacyclins. This attractive clinical profile will allow Johnson & Johnson to expand the role of the prostacyclin class in the treatment of PH, which is typically reserved as a later-line therapy.

Furthermore, Uptravi is being investigated in a triple combination regimen with a phosphodiesterase 5 (PDE5) inhibitor and Johnson & Johnson's endothelin receptor antagonist (ERA) Opsumit. This may encourage physicians to treat newly diagnosed patients aggressively with improved outcomes, while consolidating both Uptravi and Opsumit as leaders within the PH market.

Key Topics Covered:

1. Drug Overview
2. Product Profiles
3. Uptravi: Pulmonary hypertension

LIST OF FIGURES

• Uptravi for pulmonary hypertension - SWOT analysis
• The authors drug assessment summary of Uptravi for pulmonary hypertension
• The authors drug assessment summary of Uptravi for pulmonary hypertension
• Uptravi sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

• Uptravi drug profile
• Uptravi pivotal trial data in pulmonary hypertension
• Uptravi ongoing late-phase trials in pulmonary hypertension
• Uptravi sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country M, 2016-25

For more information about this report visit https://www.researchandmarkets.com/r/h1rs43

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets